Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saizen solution immunogenicity study in adults with growth hormone deficiency
2010-023430-23Phase 3Completed
- Sponsor
- Merck KGaA
- Start
- Nov 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of somatropin in growth hormone deficiency (GHD), sponsored by Merck KGaA. Primary endpoint: Proportion of subjects developing binding antibodies to Saizen. Started Nov 2010; status: completed.
02
Drugs
somatropin
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on 2010-023430-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023430-23.